$ANIX

Titterton Lewis H jr purchased $7K of ANIX

Titterton Lewis H jr purchased 2,836 shares of Anixa Biosciences Inc (ANIX) at $2.64 on 2026-06-16.

Original reporting
SEC EDGAR · Titterton Lewis H jr
Published Jun 17, 2026, 3:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 3:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANIX
Bullish
low confidence
Mentioned
$ANIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (shares, price, total value) disclosed on 2026-06-17 for a trade dated 2026-06-16.

02

Market read

Traders may treat the filing as a small sentiment input, but it does not provide new fundamentals or guidance.

03

What to watch

Check whether the director has a history of buys/sells and whether there are concurrent corporate events (financing, trial updates) not mentioned here.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-17; transaction dated 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure for Anixa Biosciences (ANIX).

Company-level read

Ticker impact

$ANIXBullishLow confidence
Context

Anixa Biosciences director Titterton Lewis H jr filed a Form 4 open-market purchase of 2,836 shares at $2.6400 on 2026-06-16.

Expected impact

Near-term impact likely limited; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The disclosure is a routine Form 4 insider purchase with no new operational/financial catalyst, and the transaction size is small relative to typical market-moving thresholds.

Market effects

Minimal; single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary and may not reflect a durable thesis; without a 10b5-1 plan, timing could be opportunistic rather than informational.

Key entities

  • Anixa Biosciences Inc

    Subject of the Form 4 insider transaction disclosure.

  • Titterton Lewis H jr

    Director who reported an open-market purchase of ANIX shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANIXMedAI 8/10

RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.

$DELLLow

Silver Lake Partners IV, L.P. (Durban Egon) sold $28.0M of DELL (indirect holdings)

Silver Lake Partners IV, L.P. sold 50,728 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $552.61 ($542.78–$563.66, $28.03M total) across 21 trades on 2026-09-15. Filed jointly with Silver Lake Technology Associates IV, L.P. (Director), SLTA IV (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).